about
Effects of clofazimine alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosyCorticosteroids in the adjunctive therapy of community-acquired pneumonia: an appraisal of recent meta-analyses of clinical trialsEpidemiology, virulence factors and management of the pneumococcusAccelerated calcium influx and hyperactivation of neutrophils in chronic granulomatous diseaseFormoterol is more effective than salmeterol in suppressing neutrophil reactivityOverview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease.Proinflammatory interactions of pneumolysin with human neutrophils.Beneficial and Harmful Interactions of Antibiotics with Microbial Pathogens and the Host Innate Immune SystemCysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell functionExposure of a 23F serotype strain of Streptococcus pneumoniae to cigarette smoke condensate is associated with selective upregulation of genes encoding the two-component regulatory system 11 (TCS11).The prevalence of smoking and the knowledge of smoking hazards and smoking cessation strategies among HIV- positive patients in Johannesburg, South AfricaRecent advances in our understanding of Streptococcus pneumoniae infection.Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.HLA-DRB1 shared epitope genotyping using the revised classification and its association with circulating autoantibodies, acute phase reactants, cytokines and clinical indices of disease activity in a cohort of South African rheumatoid arthritis patiPathogen- and host-directed anti-inflammatory activities of macrolide antibioticsInhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in miceSystemic Immune Activation Profiles of HIV-1 Subtype C-Infected Children and Their MothersA 10 years audit of cardiothoracic referrals from a pulmonology service in a developing country: impact of patient human immunodeficiency virus statusSerum matrix metalloproteinase-3 in comparison with acute phase proteins as a marker of disease activity and radiographic damage in early rheumatoid arthritis.Controversies in the treatment of pneumococcal community-acquired pneumonia.New insights into pneumococcal disease.Therapy for pneumococcal bacteremia: monotherapy or combination therapy?Protein kinase C promotes restoration of calcium homeostasis to platelet activating factor-stimulated human neutrophils by inhibition of phospholipase CThe beta-2-adrenoreceptor agonists, formoterol and indacaterol, but not salbutamol, effectively suppress the reactivity of human neutrophils in vitro.Circulating biomarkers of immune activation distinguish viral suppression from nonsuppression in HAART-treated patients with advanced HIV-1 subtype C infection.Antibiotic resistance of pathogens causing community-acquired pneumonia.Pharmacological approaches to regulate neutrophil activity.HIV-associated bacterial pneumonia.Review: current and new generation pneumococcal vaccines.Community-Acquired Pneumonia: Pathogenesis of Acute Cardiac Events and Potential Adjunctive Therapies.Impact of HIV infection and smoking on lung immunity and related disorders.Reliable and cost-effective serodiagnosis of rheumatoid arthritis.Smoking and Air Pollution as Pro-Inflammatory Triggers for the Development of Rheumatoid Arthritis.Bacterial Respiratory Infections Complicating Human Immunodeficiency Virus.Community-acquired pneumonia: still a major burden of disease.HIV-related pneumococcal disease prevention in adults.Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline.The Role of Streptococcus pneumoniae in Community-Acquired Pneumonia.Pneumolysin as a potential therapeutic target in severe pneumococcal disease.Prooxidative activities of 10 phenazine derivatives relative to that of clofazimine.
P50
Q24681758-C15081EB-9B90-4D48-9DDA-6FA4DD13ABBFQ26748532-39B8F11C-1DAA-4961-B827-B5B0F0AEF57BQ28078832-30E87493-88CF-4815-B2C8-79C54F009C33Q28350996-FAA2F92C-0F99-438A-B892-36EEB2A20841Q28596768-FE2DF7CB-366D-4A99-AEB8-AD645DE2AD4EQ30358199-387860C3-A8D7-4F50-951F-088145204856Q31918190-E3CDB5E0-6A25-4A1A-A1FB-32F9C6F9FB49Q33664362-751FCECC-8F63-4548-80D9-BD5AA73AA9BDQ33757657-26C0EA59-EEF7-47C1-94B4-ACA7CD8399A8Q33809958-5629A372-ED5E-44EA-AA2E-7C512D6451DCQ33957930-02020C40-3D8C-4EFB-BC3A-8D9F4B78E072Q34201900-6A4E3074-75F8-4111-98B2-985AE977EC6CQ35645491-6EDF2836-7168-44C7-89E1-DE10BFC92253Q35840775-A279CE2E-C820-4CEF-BE6C-DDF77E79552DQ36072425-40E0AD80-EDDC-4DF1-8617-E7BDDC045105Q36558489-2DE46C7E-3806-4564-9EA9-6761535F546AQ36670411-E1898A00-DF81-4DC2-8435-7C10442D7AE9Q36829239-0B2FDE35-9917-4EDD-9EEB-03FE60E31CE0Q36830906-C5B411C4-4DB2-44A3-ADD7-FA0244DC7C9EQ36895630-CA60A42E-2475-43A5-BF5D-C97FD6C85B3CQ37409532-9145EAB4-20E1-45C2-BF1B-8D7BAFF7A201Q37412125-787549C7-0FFB-45FC-B449-238C75FEF7B0Q37422450-F4E0BC89-25C1-4F36-978E-C07FD8698002Q37661542-AB84FDBB-5296-4BD4-BAC2-7997F6E8AC6CQ37720298-DAC90DF3-3D2D-44C9-AB7E-F4C37B387AB0Q38020407-1301A3DE-25BD-4A07-A77A-126D57BE134DQ38089635-7DDFCD5A-73F9-4ECA-908E-ACAFD909599AQ38108965-E40735D6-0747-48D7-A91A-35916197E0EFQ38223460-3674885A-CFAC-41FA-8441-2AD4831367E0Q38464563-E6FCA887-EFED-4983-A606-A3A02A0F96C2Q38562092-F9F0BABD-AC84-4270-B897-710CE8504A26Q38726475-ADD42B68-6193-4B6F-9932-4D52E623E447Q38766413-B4CB0086-D511-48D7-A5AE-5C49A86FEC5EQ38773777-6DB3165E-DA8F-4BB9-A433-6EBDC3B311E3Q38943520-27FE55A6-3533-457E-BC7E-0C20331796EEQ38947827-1266B849-969F-4C4D-9600-B409F92D8CA9Q38995175-04BFCF93-0F65-4451-A4B2-FD398AE80DE8Q39037615-E65F971E-B2E3-4987-AD6F-0CAF81280CB5Q39189832-C172B302-40A6-42A7-AD1F-548205125FB3Q39828201-0931FFCB-47D4-4770-ACCB-29843D55272E
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ronald Anderson
@ast
Ronald Anderson
@en
Ronald Anderson
@es
Ronald Anderson
@nl
type
label
Ronald Anderson
@ast
Ronald Anderson
@en
Ronald Anderson
@es
Ronald Anderson
@nl
prefLabel
Ronald Anderson
@ast
Ronald Anderson
@en
Ronald Anderson
@es
Ronald Anderson
@nl
P106
P1153
7406489754
P31
P496
0000-0002-5925-6452